Translating Research into Next Generation Care Through Collaboration


Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Read More About Us

Enterprise Innovation Metrics from FY18 to FY23

520
New Tech Disclosures
183
Issued US Patents
152
Licenses and Options
29
NewCo Launches

  

  

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

  

  

Testimonials

Dr. John Leonard
John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives
Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.
Lisa Placanica, Ph.D.
Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing
There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.
Neel Madhukar, Ph.D.
Neel Madhukar, Ph.D., Former Postdoc of the Elemento Lab and current CEO of OneThree Biotech
Taking a new technology from an idea to a company is a daunting process for first-time entrepreneurs – and especially in areas like commercialization which isn't a focus of most doctoral work. One thing that helps this is a community of scientists and entrepreneurs who have been through this before and help guide the way. In this way, resources such as the eLab’s Entrepreneurs-in-Residence are invaluable assets.
Francis Barany, Ph.D.
Francis Barany, Ph.D., Professor of Microbiology and Immunology and National Academy of Inventors Fellow
The professionals at Enterprise Innovation possess strong first-hand knowledge of what it takes to start a company. Their expertise is vital to aspiring faculty scientist/entrepreneurs to launch new companies. Their guidance and feedback has been invaluable throughout the process – they are now helping me with my third company launch.

Gut Microbiota Acts Like an Auxiliary Liver

April 23, 2024

Microbes in the mammalian gut can significantly change their hosts’ amino acid and glucose metabolism, acting almost like an extra liver, according to a new preclinical study by Weill Cornell Medicine investigators. The study, published April 23 in Cell Host & Microbe, adds to the growing list of ways in which the microbiome influences physiology, and could lead to new strategies to treat conditions such as inflammatory bowel disease and diabetes.

Tracking a Protein’s Fleeting Shape Changes

April 17, 2024

Researchers at Weill Cornell Medicine have developed a powerful, new technique to generate “movies” of changing protein structures and speeds of up to 50 frames per second.